[1] Smith, S.R., Denhardt, G., Terminelli, C. The antiinflammatory
activities of cannabinoid receptor ligands in
mouse peritonitis models, European Journal of
Pharmacology, 432 (1), 107–119, 2001.
[2] Ochi, T., Yamane-Sugiyama, A., Ohkubo, Y.,
Sakane, K., Tanaka, H. The anti-inflammatory effect of
FR188582, a highly selective inhibitor of cyclooxygenase-2,
with an ulcerogenic sparing effect in rats, Japanese Journal
of Pharmacology, 85 (2), 175–182, 2001.
[3] Maggio, B., Daidone, G., Raffa, D., Plescia, S.,
Mantione, L., Cutuli, V.M.C., Mangano, N.G., Caruso, A.
Synthesis and pharmacological study of ethyl 1-methyl-5-
(substituted 3,4-dihydro-4-oxoquinazolin-3-yl)-1Hpyrazole-
4-acetates, European Journal of Medicinal
Chemistry, 36 (9), 737–742, 2001.
[4] Umesha, K.B., Rai, K.M.L., Nayaka, M.A.H.
Antioxidant and Antimicrobial Activity of 5-methyl-2-(5-
methyl-1,3-diphenyl-1H-pyrazole-4-carbonyl)-2,4-dihydropyrazol-
3-one, International Journal of Biomedical Science,
5 (4), 359–368, 2009.
[5] Abdel-Hafez, E.S.M.N., Abuo-Rahma, G.E.D.A.A., Abdel-Aziz, M., Radwan, M.F., Farag, H.H. Design, synthesis and biological investigation of certain pyrazole-3-carboxylic acid derivatives as novel carriers for nitric oxide, Bioorganic & Medicinal Chemistry, 17 (11), 3829–3837, 2009.
[6] Vicentini, C.B., Manfrini, M., Mazzanti, M., Scatturin, A., Romagnoli, C., Mares, D. Synthesis of a novel series of imidazo[4,5-c]pyrazole derivatives and their evaluation as herbicidal agents, Archiv der Pharmazie, 332 (10), 337–342, 1999.
[7] Storer, R., Ashton, C.J., Baxter, A.D., Hann, M.M., Marr, C.L.P., Mason, A.M., Mo, C.L., Myers, P.L., Noble, S.A., Penn, C.R., Weir, N.G., Woods, J.M., Coe, P.L. The synthesis and antiviral activity of 4-fluoro-1-beta-D-ribofuranosyl-1H-pyrazole-3-carboxamide, Nucleosides & Nucleotides, 18 (2), 203–216, 1999.
[8] Zhang, Y., Burges, J.P., Brackeen, M., Gilliam, A., Mascarella, S.W., Page, K., Seltzman, H.H., Thomas, B.F. Conformationally constrained analogues of N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716): Design, synthesis, computational analysis, and biological evaluations, Journal of Medicinal Chemistry, 51 (12), 3526–3539, 2008.
[9] Srivastava, B.K., Joharapurkar, A., Raval, S., Patel, J.Z., Soni, R., Raval, P., Gite, A., Goswami, A., Sadhwani, N., Gandhi, N., Patel, H., Mishra, B., Solanki, M., Pandey, B., Jain, M.R., Patel, P.R. Diaryl dihydropyrazole-3-carboxamides with significant in vivo antiobesity activity related to CBI receptor antagonism: Synthesis, biological evaluation, and molecular modeling in the homology model, Journal of Medicinal Chemistry, 50 (24), 5951–5966, 2007.
[10] Sasmal, P.K., Reddy, D.S., Talwar, R., Venkatesham, B., Balasubrahmanyam, D., Kannan, M., Srinivas, P., Kumar, K.S., Devi, B.N., Jadhav, V.P., Khan, S.K., Mohan, P., Chaudhury, H., Bhuniya, D., Iqbal, J., Chakrabarti, R.. Novel pyrazole-3-carboxamide derivatives as cannabinoid-1 (CB1) antagonists: Journey from non-polar to polar amides, Bioorganic & Medicinal Chemistry Letters, 21 (1), 562–568, 2011.
[11] Jbilo, O., Ravinaet-Trillou, C., Arnone, M., Buisson, I., Bribes, E., Péleraux, A., Pénarier, G., Soubrié, P., Le Fur, G., Galiègue, S., Casellas, P. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance, The FASEB Journal, 19 (11), 1567–1569, 2005.
[12] Srivastava, B.K., Soni, R., Patel, J.Z., Jha, S., Shedage, S.A., Gandhi, N., Sairam, K.V.V.M., Pawar, V., Sadhwani, N., Mitra, P., Jain, M.R., Patel, P.R. Facile synthesis, ex-vivo and in vitro screening of 3-sulfonamide derivative of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide (SR141716) a potent CB1 receptor antagonist, Bioorganic & Medicinal Chemistry Letters, 18 (14), 3882–3886, 2008.
[13] Murineddu, G., Ruiu, S., Loriga, G., Manca, I., Lazzari, P., Reali, R., Pani, L., Toma, L., Pinna, G.A. Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide, Journal of Medicinal Chemistry, 48 (23), 7351–7362, 2005.
[14] Szabo, G., Varga, B., Payer-Lengyel, D., Szemzo, A., Erdelyi, P., Vukics, K., Szikra, J., Hegyi, E., Vastag, M., Kiss, B., Laszy, J., Gyertyan, I., Fischer, J. Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists, Journal of Medicinal Chemistry, 52 (14), 4329–4337, 2009.
[15] Kasimogullari, R., Bulbul, M., Arslan, B.S. and Gokce, B. Synthesis, characterization and antiglaucoma activity of some novel pyrazole derivatives of 5-amino-1,3,4-thiadiazole-2-sulfonamide, European Journal of Medicinal Chemistry, 45 (11), 4769–4773, 2010.
[16] Kasimogullari, R., Bulbul, M., Mert, S. and Guleryuz, H. Synthesis of 5-amino-1,3,4-thiadiazole-2-sulfonamide derivatives and their inhibition effects on human carbonic anhydrase isozymes, Journal of Enzyme Inhibition and Medicinal Chemistry, 26 (2), 231–237, 2011.
[17] Kasimogullari, R., Bulbul, M., Gunhan, H. and Guleryuz, H. Effects of new 5-amino-1,3,4-thiadiazole-2-sulfonamide derivatives on human carbonic anhydrase isozymes, Bioorganic & Medicinal Chemistry, 17 (9), 3295–3301, 2009.
[18] Sener, A., Kasimogullari, R., Sener, M.K., Bildirici, I., Akcamur, Y. Studies on the reactions of cyclic oxalyl compounds with hydrazines or hydrazones II [1]: Synthesis and reactions of 4-benzoyl-1-(3-nitrophenyl)-5-phenyl-1H-pyrazole-3-carboxylic acid, Journal of Heterocyclic Chemistry, 39 (5), 869–875, 2002.
[19] Kasimogullari R. and Arslan, B.S. Synthesis and characterization of some pyrazole derivatives of 1,5-diphenyl-1H-pyrazole-3,4-dicarboxylic acid, Journal of Heterocyclic Chemistry, 47 (5), 1040–1048, 2010.
Thank you for copying data from http://www.arastirmax.com
